LBA47Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511). (23rd October 2018) - Lebbé, C; Meyer, N; Mortier, L; Marquez-Rodas, I; Robert, C; Rutkowski, P; Menzies, A M; Eigentler, T; Ascierto, P A; Smylie, M; Ajaz, M; Svane, I-M; et al.